TrialCancer immunology, immunotherapy : CII2024

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.

Gerald S Falchook et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.